Detalles de la búsqueda
1.
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
Clin Gastroenterol Hepatol
; 18(2): 468-476.e11, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31376493
2.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
JAMA
; 313(12): 1223-31, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25706092
3.
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
J Hepatol
; 58(4): 663-8, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23183528
4.
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
Int J Infect Dis
; 103: 25-32, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33186704
5.
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19.
medRxiv
; 2020 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32511656
6.
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.
AIDS
; 30(6): 869-78, 2016 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26636929
7.
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Lancet HIV
; 2(8): e319-27, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26423374
8.
Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
Antivir Ther
; 7(3): 199-209, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12487388
9.
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
J Int AIDS Soc
; 17(4 Suppl 3): 19500, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25394009
10.
Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.
AIDS Res Hum Retroviruses
; 29(2): 250-5, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22738014
11.
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
J Acquir Immune Defic Syndr
; 64(2): 167-73, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23797691
12.
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
PLoS One
; 8(5): e63818, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23717490
13.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lancet Infect Dis
; 13(5): 401-8, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23499158
14.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
AIDS
; 25(14): 1737-45, 2011 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21716073
Resultados
1 -
14
de 14
1
Próxima >
>>